4-((trans-4-aminocyclohexyl)amino)-2-(butylamino)-N-(4-(morpholinosulfonyl)phenyl)pyrimidine-5-carboxamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-((trans-4-aminocyclohexyl)amino)-2-(butylamino)-N-(4-(morpholinosulfonyl)phenyl)pyrimidine-5-carboxamide
• 化学式: C₂₅H₃₇N₇O₄S
• 分子量: 531.679
• InChiKey: IJBQYPBBOUFSEN-WGSAOQKQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.64
• 重原子数：
  37.0
• 可旋转键数：
  10.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  151.57
• 氢给体数：
  4.0
• 氢受体数：
  9.0

反应信息

• 作为产物：
  描述：

  4-(吗啉磺酰)苯胺 在 N,N-二异丙基乙胺 作用下， 以 异丙醇 为溶剂， 反应 5.67h， 生成 4-((trans-4-aminocyclohexyl)amino)-2-(butylamino)-N-(4-(morpholinosulfonyl)phenyl)pyrimidine-5-carboxamide
  参考文献：
  名称：

  Discovery of Mer Specific Tyrosine Kinase Inhibitors for the Treatment and Prevention of Thrombosis

  摘要：

  The role of Mer kinase in regulating the second phase of platelet activation generates an opportunity to use Mer inhibitors for preventing thrombosis with diminished likelihood for bleeding as compared to current therapies. Toward this end, we have discovered a novel, Mer kinase specific substituted-pyrimidine scaffold using a structure-based drug design and a pseudo ring replacement strategy. The cocrystal structure of Mer with two compounds (7 and 22) possessing distinct activity have been determined. Subsequent SAR studies identified compound 23 (UNC2881) as a lead compound for in vivo evaluation. When applied to live cells, 23 inhibits steady-state Mer kinase phosphorylation with an IC50 value of 22 nM. Treatment with 23 is also sufficient to block EGF-mediated stimulation of a chimeric receptor containing the intracellular domain of Mer fused to the extracellular domain of EGFR. In addition, 23 potently inhibits collagen-induced platelet aggregation, suggesting that this class of inhibitors may have utility for prevention and/or treatment of pathologic thrombosis.

  DOI：

  10.1021/jm4013888

文献信息

• THERAPEUTIC USES OF SELECTED PYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY
  申请人：The University of North Carolina at Chapel Hill

  公开号：US20150290194A1

  公开（公告）日：2015-10-15

  Uses of pyrimidines with anti-Mer tyrosine kinase activity as anti-infective agents, immunostimulatory and immunomodulatory agents, anti-cancer agents (including against MerTK −/− tumors and ITD and TKD mutant forms of Acute Myeloid Leukemia (AML)), and as adjunctive agents in combination with chemotherapeutic, radiation or other standard of care for neoplasms.

  嘌呤类化合物具有抗Mer酪氨酸激酶活性，并可用作抗感染剂、免疫刺激剂和免疫调节剂、抗癌剂（包括对MerTK -/- 肿瘤和急性髓细胞白血病（AML）的ITD和TKD突变形式），以及与化疗、放疗或其他标准护理方法结合使用的辅助剂。
• US9567326B2
  申请人：——

  公开号：US9567326B2

  公开（公告）日：2017-02-14
• US9649309B2
  申请人：——

  公开号：US9649309B2

  公开（公告）日：2017-05-16
• Discovery of Mer Specific Tyrosine Kinase Inhibitors for the Treatment and Prevention of Thrombosis
  作者：Weihe Zhang、Andrew L. McIver、Michael A. Stashko、Deborah DeRyckere、Brian R. Branchford、Debra Hunter、Dmitri Kireev、Michael J. Miley、Jacqueline Norris-Drouin、Wendy M. Stewart、Minjung Lee、Susan Sather、Yingqiu Zhou、Jorge A. Di Paola、Mischa Machius、William P. Janzen、H. Shelton Earp、Douglas K. Graham、Stephen V. Frye、Xiaodong Wang

  DOI：10.1021/jm4013888

  日期：2013.12.12

  The role of Mer kinase in regulating the second phase of platelet activation generates an opportunity to use Mer inhibitors for preventing thrombosis with diminished likelihood for bleeding as compared to current therapies. Toward this end, we have discovered a novel, Mer kinase specific substituted-pyrimidine scaffold using a structure-based drug design and a pseudo ring replacement strategy. The cocrystal structure of Mer with two compounds (7 and 22) possessing distinct activity have been determined. Subsequent SAR studies identified compound 23 (UNC2881) as a lead compound for in vivo evaluation. When applied to live cells, 23 inhibits steady-state Mer kinase phosphorylation with an IC50 value of 22 nM. Treatment with 23 is also sufficient to block EGF-mediated stimulation of a chimeric receptor containing the intracellular domain of Mer fused to the extracellular domain of EGFR. In addition, 23 potently inhibits collagen-induced platelet aggregation, suggesting that this class of inhibitors may have utility for prevention and/or treatment of pathologic thrombosis.